Term
|
Definition
| Inflammation w/in brain and spinal cord --> plaques/sclerosis --> demyelinization of sheath surrounding neurons |
|
|
Term
|
Definition
|
|
Term
|
Definition
1. Relapsing-Remitting (>24h sx then 30d no sx)
2. Primary Progressive (only ever gets worse)
3. Secondary Progressive (combo, but pt never returns to baseline) |
|
|
Term
|
Definition
1. Tx acute exacerbations
2. Alter disease process
3. Alleviate ongoing sx |
|
|
Term
|
Definition
| Interferon beta or glatiramer |
|
|
Term
| Tx acute excerbations with: |
|
Definition
| IV Methylprednisolone 50-100mg/day for 3-5d +/- oral taper |
|
|
Term
| 12 approved disease modifying drugs (DMD) of MS |
|
Definition
interferon-B1a (Avonex/Refib)
interferon-B1b (Betaseron/Extivia)
peginterferon-B1a (Plegridy)
glatiramer (Copaxone)
natalizumab (Tysabri)
Mitoxantrone (Novantrone)
dimethyl fumerate (Tecfidera)
Teriflunomide (Aubagio)
Fingolimod (Gilenya)
Alemtzumab (Lemtrada) |
|
|
Term
|
Definition
Fingolimod (Gilenya)
dimethyl fumerate (Tecfidera)
Teriflunomide (Aubagio)
Dalfampridi (Ampyra) ***Not a DMD; sx mgmt*** |
|
|
Term
|
Definition
natalizumab (Tysabri)
Mitoxantrone (Novantrone)
Alemtzumab (Lemtrada) |
|
|
Term
| Perals: Natalizumab (Tysabri) |
|
Definition
1. reserved for pts that do not respond to firstline agents (interferons or glatiramer)
2. Only Avaliable through restrictive rx program: TOUCH program due to S/E of PML
3. IV dosing |
|
|
Term
| Pearls: dimethyl fumerate (Tecfidera) |
|
Definition
1. approved for relapsing MS
2. Oral dosing
3. Place in tx is not fully known |
|
|
Term
| Pearls: Alemtzumab (Lemtrada) |
|
Definition
| 1. approved for relapsing MS |
|
|
Term
| Pearls: Mitoxantrone (Novantrone) |
|
Definition
1. Only agent approved for worsening relasping-remitting MS and progressive MS
2. Only drug that might be used in combo with another DMD "pulse therapy"
3. IV dosing
4. BBW for cardiovascular risk |
|
|
Term
| Pearls: Interferons (Avonex/Refib/Betaseron/Extivia/Plegridy) |
|
Definition
1. SQ/IM dosing
2. Flu-like sx
3. 1rst line
4. Can lose efficacy overtime due to nuetalizing antibody production
5. Protect from light |
|
|
Term
| Pearls: Glatiramer (Copaxone) |
|
Definition
1. SQ dosing
2. Does not produce neutralizing antibodies ( |
|
|
Term
| Pearls: Fingolimod (Gilenya) |
|
Definition
1. Oral dosing
2. S/E: Gradicardia/HTN/QTC prolongation |
|
|
Term
| Pearls: Teriflunomide (Aubagio) |
|
Definition
1. Oral dosing
2. BBW for liver risks |
|
|
Term
| Pearls: Dalfampridi (Ampyra) |
|
Definition
1. Approved for sx mgmt; not DMD
2. indication = improved walking
3. Seizure risk |
|
|
